Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02456701
What this trial is testing

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Who this might be right for
Thyroid Cancer
Celldex Therapeutics 7
Not applicableApproved For MarketingNCT02211222
What this trial is testing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Eisai Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Not applicableNot Yet RecruitingNCT07770074
What this trial is testing

A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Who this might be right for
Radioiodine-refractory Differentiated Thyroid Cancer
Novartis Pharmaceuticals 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT04560127
What this trial is testing

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02390934
What this trial is testing

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Early research (Phase 1)Study completedNCT01709435
What this trial is testing

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Primary Central Nervous System Neoplasm+4 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Looking for participantsNCT06359847
What this trial is testing

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited 60
Testing effectiveness (Phase 2)UnknownNCT03732495
What this trial is testing

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Who this might be right for
Thyroid Cancer Metastatic
Centre Leon Berard 35
Testing effectiveness (Phase 2)Study completedNCT01502410
What this trial is testing

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Who this might be right for
Childhood Hepatocellular CarcinomaPapillary Thyroid CancerPreviously Treated Childhood Rhabdomyosarcoma+4 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Ended earlyNCT01552434
What this trial is testing

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Who this might be right for
Advanced Malignant NeoplasmCastleman DiseaseDigestive System Carcinoma+36 more
M.D. Anderson Cancer Center 154
Not applicableStudy completedNCT03363347
What this trial is testing

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Heidelberg University 25
Testing effectiveness (Phase 2)UnknownNCT01830504
What this trial is testing

Phase II Pilot Open Label

Who this might be right for
Thyroid Cancers
Hospices Civils de Lyon 47
Testing effectiveness (Phase 2)UnknownNCT04619316
What this trial is testing

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Who this might be right for
Metastatic Thyroid Cancer
University Hospital, Essen 70
Testing effectiveness (Phase 2)Study completedNCT01813136
What this trial is testing

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Centre Leon Berard 168
Testing effectiveness (Phase 2)UnknownNCT05182931
What this trial is testing

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Who this might be right for
Thyroid Cancer
Olivia Newton-John Cancer Research Institute 80
Testing effectiveness (Phase 2)Ended earlyNCT02472080
What this trial is testing

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

Who this might be right for
Thyroid Cancer
Assistance Publique - Hôpitaux de Paris 21
Early research (Phase 1)Study completedNCT05241834
What this trial is testing

LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company 70
Testing effectiveness (Phase 2)Study completedNCT01025453
What this trial is testing

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Who this might be right for
Thyroid Cancer
Memorial Sloan Kettering Cancer Center 37
Next Page